Clinical Trial Detail

NCT ID NCT01895842
Title Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements yes
Sponsors M.D. Anderson Cancer Center|Incyte Corporation
Indications

bone marrow cancer

Therapies

Ruxolitinib

Age Groups: adult

Additional content available in CKB BOOST